Proove Biosciences Introduces Three New Profiles to Help Clinicians Improve Treatment Decisions

IRVINE, CA--(Marketwired - Jul 11, 2016) - Proove Biosciences, Inc. is pleased to announce the introduction of three new evidence-based tests to support better clinical decision-making for difficult-to-treat conditions that are influenced by genetics. Proove's new profiles help improve outcomes for patients who are at risk for -- or suffering from -- substance abuse, fibromyalgia and venous thromboembolism.

"Clinicians come to us with questions that demand a different type of thinking. By researching the genetic and clinical factors that contribute to risk along with the factors that help define the most appropriate treatment approaches, we are able to deliver answers that help improve healthcare decisions," says Brian Meshkin, founder and CEO of Proove Biosciences. "Whether it is the role of genetics in substance abuse, the confusion around understanding fibromyalgia, or the fear of venous thromboembolism for a patient undergoing orthopedic surgery, these new profiles are ultimately about facilitating better decisions to improve patient care."

Building on the considerable success of the company's bioinformatics platform for collecting, storing, analyzing, and integrating biological and genetic information into clinical decision-improvement tools, Proove researchers and developers have created these latest profiles to help physicians treat patients in pain, which is the nation's largest and most expensive healthcare condition.

• With the tremendous overlap between pain, mental health and addiction, Proove's leading bioinformatics platform has produced the Proove Addiction™ Profile to address the growing epidemic of substance abuse, which results in more than 550,000 deaths annually from alcohol, nicotine, heroin, cocaine and methamphetamines. The Proove Addiction Profile, therefore, utilizes objective genetic data to help physicians identify patients who may be at greater risk of dependence or may experience worse outcomes with substance use. Furthermore, this profile provides physicians with knowledge-based medication recommendations that can be used to guide treatment strategies for patients who are already diagnosed with substance use disorders.
  
  
• Fibromyalgia is a complex centralized pain condition that is often difficult to treat and diagnose. The Proove Fibromyalgia™ Profile is a first-of-its-kind decision-improvement tool that harnesses individualized information to aid in the identification of genetic factors that may contribute to differing clinical pathways behind a fibromyalgia diagnosis and in the customization of personalized treatment. The profile allows for the targeting and analysis of genetic markers that play a role in the efficacy of drug therapies designed to ameliorate the condition, which is believed to be partially caused by reduced turnover of serotonin, norepinephrine and dopamine. The test can be administered for patients who may have fibromyalgia or for those who have already been diagnosed.
  
  
• A major concern for orthopedic surgeons surrounds a patient's potential development of venous thromboembolism (VTE). The Proove Thromboembolism™ Profile tackles the difficulties surrounding venous thromboembolism (VTE), which is the third most common cardiovascular illness after acute coronary syndrome and stroke. Approximately one million cases occur each year, many of which represent recurrent disease. In addition to acquired risk factors, including hypertension, diabetes, smoking and high cholesterol levels, researchers have long known that genetic predisposition is a prominent risk factor for patients. This profile provides physicians with the means by which to analyze genetic variations (or polymorphisms) that are risk factors for venous thromboembolism. In addition to stratifying patients into low, moderate or high clinical probability of thromboembolic complications and enhancing the reliability of effective diagnosis, the test provides clinically actionable recommendations for prophylactic treatment.
  
  

"These tests continue to advance our mission of taking complex information and turning it into understandable and actionable insights to improve health," says Svetlana Kantorovich, Ph.D., Director of Clinical & Scientific Affairs at Proove Biosciences. "The combination of clinical data with genetic information allows Proove to create unique one-of-a-kind profiles that aid healthcare professionals in their healthcare decisions to improve outcomes and reduce costs."

To learn more about Proove Biosciences, visit www.proove.com. With media inquiries, please contact Leslie Licano at leslie@beyondfifteen.com or (949)-733-8679.

About Proove Biosciences: Proove Biosciences -- the Healthcare Decision Company™ -- is the commercial and educational leader in the research, investigation and development of patent-protected tests that combine genetic and clinical data into reports to help physicians to individualize -- and optimize -- medicine selection and dosing. Supported by leading medical experts and institutions across the globe, the reports facilitate objective decision-making to improve outcomes for patients, providers and insurers. Backed by science and driven by data, Proove is revolutionizing individualized medicine. With a patented bioinformatics platform that delivers therapy-defining information that allows prescribers to evaluate pain tolerance, assess patient drug metabolism, predict response and immunity to opioid and non-opioid pain medication, and identify risk for dependence and addiction, Proove provides the most technologically advanced solutions to enable accurate and evidence-based medical decision-making rather than "trial-and-error" approaches. Proove helps reduce the risk of treatment failure, decrease costs to insurers and relieve society of the emotional and financial burdens associated with addiction and other avoidable consequences. For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).